Hueber Arno, Esser Johannes M, Kociok Norbert, Welsandt Gerhard, Lüke Christoph, Roters Sigrid, Esser Peter J
Centre of Ophthalmology, University of Cologne, Cologne, Germany.
Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):297-304. doi: 10.1007/s00417-007-0695-1. Epub 2007 Oct 13.
Despite the adjuvant use of mitomycin C during trabeculectomy, failures still occur. We investigated whether cultured human Tenon fibroblasts exposed to low-dose mitomycin C developed a multidrug resistance phenotype in vitro, and whether mitomycin C treatment during previous filtration surgery induces P-glycoprotein expression in vivo.
Cultured human Tenon fibroblasts treated with low-dose 0.01 nM mitomycin C for 2 weeks were subsequently treated with 0.1 to 100 microM mitomycin C in the absence or presence of 4 microM verapamil, and allowed to recover for 24 hours. Low-dose mitomycin C-treated fibroblasts were analysed for P-glycoprotein expression using flow cytometry, immunoblotting, and RT-PCR for mdr-1 mRNA. In addition, fibroblasts were treated with low dose 0.1 nM 5-fluorouracil for 2 weeks and analysed for P-glycoprotein expression using flow cytometry. Expression of P-glycoprotein was analysed in surgically removed Tenon tissue (n = 30) using immunohistochemistry. Of the 30 patients, 20 had a previous trabeculectomy, of which nine had previous adjuvant therapy with mitomycin C during trabeculectomy.
Partial resistance to mitomycin C after low-dose mitomycin C pre-treatment was significantly neutralised by the addition of verapamil. Low-dose mitomycin C up-regulated P-glycoprotein expression, but not mdr-1 mRNA expression. 5-Fluorouracil did not induce P-glycoprotein expression. P-glycoprotein expression was detected in all nine patients exposed to mitomycin C during previous trabeculectomies. Only six of 21 specimens from patients not previously exposed to mitomycin C showed faint P-glycoprotein expression.
The induction of P-glycoprotein by mitomycin C could explain some failures that occur after repeated use of mitomycin C during trabeculectomy. The concomitant use of verapamil or the use of 5-fluorouracil alone could increase the success rate of repeat trabeculectomies.
尽管小梁切除术期间辅助使用了丝裂霉素C,但仍会出现手术失败的情况。我们研究了暴露于低剂量丝裂霉素C的培养人Tenon成纤维细胞在体外是否会形成多药耐药表型,以及先前滤过手术期间的丝裂霉素C治疗是否会在体内诱导P-糖蛋白表达。
用低剂量0.01 nM丝裂霉素C处理培养的人Tenon成纤维细胞2周,随后在不存在或存在4 μM维拉帕米的情况下,用0.1至100 μM丝裂霉素C处理,并使其恢复24小时。使用流式细胞术、免疫印迹和mdr-1 mRNA的RT-PCR分析低剂量丝裂霉素C处理的成纤维细胞的P-糖蛋白表达。此外,用低剂量0.1 nM 5-氟尿嘧啶处理成纤维细胞2周,并使用流式细胞术分析P-糖蛋白表达。使用免疫组织化学分析手术切除的Tenon组织(n = 30)中的P-糖蛋白表达。在这30例患者中,20例曾接受过小梁切除术,其中9例在小梁切除术期间曾接受过丝裂霉素C辅助治疗。
低剂量丝裂霉素C预处理后对丝裂霉素C的部分耐药性通过添加维拉帕米得到显著中和。低剂量丝裂霉素C上调了P-糖蛋白表达,但未上调mdr-1 mRNA表达。5-氟尿嘧啶未诱导P-糖蛋白表达。在先前小梁切除术中暴露于丝裂霉素C的所有9例患者中均检测到P-糖蛋白表达。在先前未暴露于丝裂霉素C的患者的21个标本中,只有6个显示出微弱的P-糖蛋白表达。
丝裂霉素C诱导P-糖蛋白可能解释了小梁切除术期间重复使用丝裂霉素C后出现的一些手术失败情况。维拉帕米的联合使用或单独使用5-氟尿嘧啶可能会提高重复小梁切除术的成功率。